New Clinical Trial started against rare liver cancer

🙁 Unfortunately, there is not yet a systematic standard therapy for advanced fibrolamellar hepatocellular carcinoma (FLC), a rare but very agressive liver cancer which occurs mainly in young patients. The team surrounding our spokesperson 👩‍🔬Prof. Dr. med. Juliane S. Walz. and iFIT Principal Investigator 👨‍🔬Helmut Salih have developed a therapeutic 💉cancer peptide vaccine Fusion-VAC-XS15 in patients with fibrolamellar hepatocellular carcinoma or other tumor diseases with evidence of the DNAJB1-PRKACA gene fusion after successful initial therapy and have started a clinical trial.

📽️In the video, Prof. Walz describes the major challenges of FLC, why their developed peptide vaccine could be a game changer and who is eligable for the study. The Fibrolamellar Cancer Foundation is providing the funding necessary to support this trial.
 

Read more: https://www.medizin.uni-tuebingen.de/en-de/fusionvac-krebsimpfstoffstudie